This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NCAN / Neurocan core protein · IHC design guide
Design Immunohistochemistry for NCAN
Plan chromogenic IHC on paraffin sections for NCAN using staining in CNS processes as a reference (HPA tissue IHC). This guide covers fixation consistency, antibody concentration, detection and interpretation of a secreted protein (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NCAN Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | CNS processes (HPA tissue IHC); secreted protein (UniProt) | |
| Staining pattern | CNS processes: synaptic glomeruli capsules and cortical neuropil (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A06700-1) | |
| Positive control | Cerebellum+3 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Secreted NCAN may stain away from RNA-positive cells (HPA tissue IHC) | |
| Regulation | Brain-enriched RNA (HPA tissue RNA) | |
| Isoform / epitope | 0 isoforms annotated; mature chain begins at residue 23 (UniProt) |
Section 1
Recommended NCAN IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet A06700-1) is accompanied by published chromogenic NCAN protocols for liver tissue (PMC12571593) and Merkel cell carcinoma tissue (PMC10162530).
| Sample | Paraffin-embedded human glioma tissue; fixative not specified (datasheet A06700-1) |
| Fixation | Image fixative and duration unreported (datasheet A06700-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A06700-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06700-1) |
| Primary antibody | Rabbit anti-NCAN, 1:100–1:500 starting range (standard) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A06700-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NCAN-positive staining in synaptic glomeruli - capsule of cerebellum (HPA tissue IHC: High). HPA tissue profile: Expression in processes in CNS. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6, as specified by the catalog datasheet (datasheet A06700-1) and used in the liver protocol (PMC12571593).
Section 2
What Is the Expected NCAN Staining Pattern?
NCAN is a secreted proteoglycan with no transmembrane segment (UniProt O14594 topology). In paraffin section IHC, expect staining associated with CNS processes: high signal in cerebellar synaptic glomeruli capsules and medium signal in cerebral cortical neuropil (HPA tissue IHC). HPA rates the tissue profile Enhanced, while noting medium consistency with RNA and disregarded presumed off target staining (HPA tissue IHC reliability).
| Structured staining outlines cerebellar synaptic glomeruli capsules; cortical neuropil also stains. | This matches the reported high cerebellar and medium cortical patterns (HPA tissue IHC). Assess the local process or extracellular pattern rather than counting positive neuronal cell bodies: NCAN is secreted and HPA describes expression in CNS processes (UniProt O14594 topology; HPA tissue IHC profile). |
| Strong staining concentrates in nuclei or forms a consistent intracellular pattern instead of following CNS processes. | Treat that compartment as suspect: NCAN is secreted, has no transmembrane segment, and HPA reports expression in processes (UniProt O14594 topology; HPA tissue IHC profile). Compare adjacent morphology and controls before scoring it as NCAN; the supplied sources do not establish a nuclear pattern. |
| Hematopoietic cells stain strongly, although the expected CNS pattern is absent. | HPA reports no detection in bone marrow hematopoietic cells (HPA tissue IHC). Consider antibody cross reactivity or endogenous chromogenic detection activity as general IHC possibilities. Staining of appendix or colon enterocyte microvilli alone is a different case: HPA reports medium signal there (HPA tissue IHC). |
| A uniform chromogenic haze obscures tissue structures and appears across expected positive and negative regions. | The haze cannot be assigned confidently to NCAN because the reported pattern is anatomically restricted (HPA tissue IHC profile). In general IHC practice, inspect secondary only and detection controls, then review antibody concentration, washing, and blocking; do not score diffuse color as extracellular NCAN solely because NCAN is secreted (UniProt O14594 topology). |
| Cerebellar synaptic glomeruli capsules show no signal in an otherwise interpretable section. | This conflicts with the reported high signal at that site (HPA tissue IHC). First verify that the region is present and that the IHC run worked; then review antibody application and retrieval using the antibody's IHC-P instructions. A negative slide by itself cannot establish absence of NCAN. |
💡Expected NCAN appearanceCall a positive result when chromogenic signal follows cerebellar synaptic glomeruli capsules at high intensity or cortical neuropil at medium intensity (HPA tissue IHC); isolated strong nuclear staining or uniform haze is discordant with the secreted, CNS process associated pattern (UniProt O14594 topology; HPA tissue IHC profile).
| Secreted topology | NCAN has a signal peptide at residues 1–22 and no transmembrane segment (UniProt O14594 topology). Interpret staining in the context of CNS processes and extracellular distribution (HPA tissue IHC profile); a membrane rim on every cell is not an expected pattern established by these sources. |
| Tissue and structure | HPA reports high signal in cerebellar synaptic glomeruli capsules, medium in cortical neuropil, and no detection in caudate glial cells (HPA tissue IHC). Select and score the named structures: brain enrichment in RNA does not mean every brain cell should stain (HPA tissue IHC RNA specificity). |
| Antibody validation | The listed rabbit polyclonal antibody HPA036814 has an Enhanced IHC designation (HPA antibodies). The tissue profile also records medium staining versus RNA consistency and presumed off target binding that was disregarded (HPA tissue IHC reliability); interpret unexpected structures against the reported pattern and controls. |
| Core protein processing and glycans | UniProt annotates a mature core protein beginning at residue 23 and six glycosylation sites (UniProt O14594 processing and glycosylation). The payload gives no antibody epitope or target specific retrieval response, so these annotations cannot identify an optimal retrieval condition or explain a failed slide. |
| Reference negatives | HPA reports no detection in adipose tissue adipocytes and bone marrow hematopoietic cells (HPA tissue IHC). These offer pattern checks when present in a study, but the stated negative result applies to those cells in those tissues; it is not a claim that all non neural tissue is negative. |
| Situation | Likely cause | Next action |
|---|---|---|
| No cerebellar capsule signal. | The positive structure may be missing from the examined field, or the IHC run may have failed; HPA reports high staining in that structure (HPA tissue IHC). | Locate synaptic glomeruli capsules on the section, check run controls, and confirm antibody handling and the antibody's IHC-P retrieval instructions. Treat retrieval changes as general workflow optimization, since NCAN specific retrieval sensitivity is unreported. |
| Strong nuclear or widespread cell body color dominates the slide. | This conflicts with NCAN's secreted topology and the reported CNS process pattern (UniProt O14594 topology; HPA tissue IHC profile); nonspecific binding or detection artifact is possible in general IHC practice. | Recheck morphology at higher magnification and compare with a secondary only control. Score the reported structures separately; do not count nuclear color as NCAN without independent support. |
| Uniform haze masks the neuropil. | Broad background prevents assessment of the medium cortical neuropil pattern (HPA tissue IHC); excess detection signal or inadequate washing are general IHC possibilities. | Inspect a no primary control, review washing and blocking, and adjust the working antibody concentration within its documented IHC-P instructions. Reassess whether anatomical detail becomes visible. |
| Unexpected color appears in bone marrow hematopoietic cells. | HPA reports these cells as not detected (HPA tissue IHC). Cross reactivity or endogenous enzyme activity can mimic chromogenic staining in general IHC practice. | Compare no primary and secondary only controls, review the detection chemistry and endogenous enzyme blocking, and require the reported CNS pattern before interpreting the unexpected signal as NCAN. |
| Enterocyte microvilli stain in appendix or colon. | This can match the reported medium microvillar staining (HPA tissue IHC), even though NCAN RNA is tissue enriched in brain (HPA tissue IHC RNA specificity). Secreted protein location and local RNA expression need not align (HPA tissue IHC reliability). | Record the precise apical structure and intensity, check run controls, and assess the cerebellar or cortical pattern on an appropriate positive control before judging specificity. |
| Can an IF/ICC image establish the expected intracellular compartment? | HPA lists NCAN as secreted but supplies no main ICC-IF location or cell line images (HPA subcellular). The supplied evidence therefore does not define an intracellular IF pattern. | Use the CNS tissue IHC pattern as the supported localization reference (HPA tissue IHC). Consult the separate IF/ICC guide for that application; do not infer an IF protocol or a cell line pattern from the IHC evidence. |
Experiment evidence
IHC & IF images showing NCAN staining
A06700-1 · IHCIHC analysis of Neurocan using anti-Neurocan antibody (A06700-1). Neurocan was detected in paraffin-embedded section of human glioma tissue.
A06700-1 · IHCIHC analysis of Neurocan using anti-Neurocan antibody (A06700-1). Neurocan was detected in paraffin-embedded section of mouse brain tissue.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000130287-NCAN/tissue/cerebral+cortex#imid_19180675
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000130287-NCAN/tissue/colon#imid_19180609
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000130287-NCAN/tissue/liver#imid_19180594
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000130287-NCAN/tissue/kidney#imid_19180595
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NCAN IHC & IF
🧪Run cerebellum first and look for staining in synaptic glomeruli capsules (HPA: High in synaptic glomeruli capsules); use adipose tissue as the negative tissue (HPA: Not detected in adipocytes). On the cerebellar slide, use cells without capsule-associated staining as candidate internal negatives, confirmed against the no-primary control; the supplied HPA row does not identify a specific negative cell type (HPA: cerebellum row).
Positive control tissue: Cerebellum (Synaptic glomeruli - capsule, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for NCAN; derive a cell-line control from the positive tissue's cell type (Synaptic glomeruli - capsule) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only) and concentration-matched rabbit IgG isotype controls for the rabbit catalog antibody; use NCAN knockout tissue, if available, as a biological negative (selected-SKU IHC caption: rabbit primary antibody; standard IHC practice). For the reported biotin-based DAB detection, block endogenous peroxidase and assess endogenous biotin background in cerebellum; assess tissue autofluorescence if adapting the assay to IF (selected-SKU IHC caption: biotinylated secondary, SABC and DAB; standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected-SKU paraffin-section caption does not state the fixative (selected-SKU IHC caption). The caption reports heat retrieval in citrate buffer at pH 6 for 20 minutes, but does not establish that retrieval is required under other conditions (selected-SKU IHC caption). The supplied evidence does not establish frozen sections or IF as easier than IHC-P; in cerebellum, check IF signal against neural-tissue autofluorescence (selected-SKU IHC caption: paraffin-section IHC; standard IF practice).
HPA tissue IHC evidence for NCAN
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex. Presumed off target binding observed and disregarded.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Synaptic glomeruli - capsule | High | Protein (IHC) | HPA → |
| Appendix | Enterocytes - Microvilli | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Colon | Enterocytes - Microvilli | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NCAN IHC Tips
Troubleshoot NCAN chromogenic IHC in paraffin sections using the documented antibody conditions and compartment-aware controls (selected IHC caption A06700-1; UniProt O14594).
Which retrieval condition should I start with for NCAN IHC?
Start with heat-mediated citrate retrieval at pH 6 for 20 minutes (datasheet A06700-1; selected IHC caption A06700-1). Keep heating uniform and sections wet, then use the same retrieval cycle across comparison slides so DAB intensity remains comparable (standard IHC practice). The documented human glioma section was blocked with 10% goat serum and incubated with 1 µg/mL primary antibody overnight (selected IHC caption A06700-1). If staining remains weak, adjust retrieval duration on adjacent sections while monitoring morphology and background, since excessive heating can damage tissue (standard IHC practice).
Could fixation explain faint NCAN staining?
No target-specific fixation comparison is supplied for NCAN, so its fixation sensitivity is unknown; the selected paraffin-section caption does not identify the fixative (selected IHC caption A06700-1). Record fixation and processing for each specimen, then compare matched sections before attributing signal loss to fixation (standard IHC practice). Hold section thickness, citrate retrieval at pH 6 for 20 minutes, and primary antibody at 1 µg/mL constant during that comparison (selected IHC caption A06700-1; standard IHC practice). Review morphology and a no-primary control alongside the reference section, because faint DAB alone does not identify the source of signal loss (standard IHC practice).
Where should NCAN staining appear in tissue sections?
Expect extracellular or process-associated staining because NCAN is secreted and lacks a transmembrane segment (UniProt O14594 subcellular location and topology). HPA describes expression in CNS processes, with high staining in cerebellar synaptic glomerular capsules and medium staining in cerebral cortical neuropil (HPA tissue IHC). Annotate the anatomical compartment rather than assuming that stain outlines the cell producing NCAN; tissue RNA and secreted protein locations can differ (HPA tissue IHC reliability note; standard IHC practice). Check adjacent morphology and a no-primary section before assigning dense deposits to NCAN, especially where tissue folds concentrate DAB (standard IHC practice).
Could an isoform or modified epitope explain patchy NCAN staining?
The supplied record lists 0 annotated isoforms and a signal peptide at residues 1–22, followed by the 23–1321 core-protein chain (UniProt O14594 processing and isoforms). It also lists 6 glycosylation sites and several distinct domains, which warrant caution when interpreting variable epitope accessibility (UniProt O14594 features; standard IHC practice). Without an epitope map for A06700-1, patchy staining cannot be assigned to a particular domain or glycoform (selected IHC caption A06700-1; standard IHC practice). Compare adjacent sections using citrate pH 6 retrieval and 1 µg/mL antibody, then inspect morphology and background controls (selected IHC caption A06700-1; standard IHC practice).
How can IF help assess an extracellular NCAN IHC pattern?
Treat IF as an exploratory assay: A06700-1 has documented paraffin-section chromogenic IHC, while HPA lists no ICC/IF images (selected IHC caption A06700-1; HPA subcellular). Multiplex NCAN with a marker for the expected local cells or processes, using 2 distinct channels and single-stain controls (HPA tissue IHC; standard IF practice). NCAN is secreted without a transmembrane segment, so begin without permeabilisation for accessible extracellular epitopes and compare permeabilised sections if testing intracellular signal (UniProt O14594 topology; standard IF practice). Choose a fluorophore away from tissue autofluorescence and compare its distribution with the DAB pattern and a no-primary control (standard IF practice).
Why does brown staining extend beyond expected NCAN regions?
Map the signal against extracellular and process-rich regions, because NCAN is secreted and HPA describes staining in CNS processes (UniProt O14594 subcellular location; HPA tissue IHC). Compare a no-primary section and inspect folds, drying artefacts and edges, where chromogen can accumulate without target binding (standard IHC practice). Quench endogenous peroxidase before DAB development and assess secondary-antibody background; the documented section used a 10% goat serum block (selected IHC caption A06700-1; standard IHC practice). If background persists, titrate around the documented 1 µg/mL primary concentration while holding citrate pH 6 retrieval and DAB development constant (selected IHC caption A06700-1; standard IHC practice).
How should I quantify NCAN in DAB-stained sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define extracellular or process-rich regions before scoring, because NCAN is secreted and HPA reports staining in CNS processes (UniProt O14594 subcellular location; HPA tissue IHC). Measure DAB-positive area or optical density per mm² of anatomically matched viable tissue, excluding folds, necrosis and section edges (standard IHC practice). If cellular staining is a prespecified endpoint, report percent positive cells or an H-score separately and state how extracellular signal was handled (standard IHC practice). Normalise to analysed tissue area, keep thresholds and scan settings consistent, and use replicate sections plus a no-primary control to estimate background (standard IHC practice).
How can I distinguish genuine NCAN staining from artefact?
Favor reproducible extracellular or process-associated DAB in plausible regions: NCAN is secreted, and HPA reports cerebellar synaptic glomerular capsules and cortical neuropil (UniProt O14594 subcellular location; HPA tissue IHC). Do not assign a dark cell body as specific solely from intensity, since secreted protein can lie beside its source cell (UniProt O14594 subcellular location; standard IHC interpretation). Compare sections for edge staining, folds and necrosis; a no-primary control helps reveal reagent background or endogenous-enzyme signal (standard IHC practice). The selected glioma image documents citrate pH 6 retrieval, but its caption alone cannot establish the specificity of every brown deposit (selected IHC caption A06700-1; standard IHC interpretation).
Boster reagents
Best NCAN / Neurocan core protein IHC Antibodies
A06700-1 has IHC images of paraffin sections from human glioma and mouse brain; the payload supplies no IF images (A06700-1 IHC and IF image fields).
Real IHC data
Anti-Neurocan/NCAN Antibody ®
Cat # A06700-1
A06700-1 lists IHC for Human, Mouse, and Rat, with IHC images from human glioma and mouse brain paraffin sections (catalog applications and reactivity; A06700-1 IHC image captions). M06700 lists IHC and Human reactivity, but supplies no IHC image (catalog applications, reactivity, and IHC image field).
Which to pick: For tissue IHC, pick A06700-1 because its own captions document staining in paraffin sections; the fixative is unreported (A06700-1 IHC image captions). For work across species, A06700-1 lists Human, Mouse, and Rat reactivity, while M06700 is a rabbit monoclonal listed for Human only (catalog reactivity, host, and clone). Neither SKU lists IF/ICC as an application, so neither has catalog support for that choice (catalog applications).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O14594 (NCAN_HUMAN, Neurocan core protein).
- Human Protein Atlas. NCAN tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. NCAN subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. NCAN antibody validation summary (1 antibodies).
- A proteome-wide association study reveals novel plasma proteins as potential therapeutic targets for metabolic dysfunction-associated steatotic liver disease. Frontiers in endocrinology 2025 — PMC12571593.
- Neural extracellular matrix regulates visual sensory motor integration. iScience 2024 — PMC10839651.
- Neurocan expression associates with better survival and viral positivity in Merkel cell carcinoma. PloS one 2023 — PMC10162530.
- Depletion of Neurocan in the Prefrontal Cortex Impairs Temporal Order Recognition, Cognitive Flexibility and Perisomatic GABAergic Innervation. Cellular and molecular neurobiology 2026 — PMC13247103.
- PubMed PMID:9795216 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
- PubMed PMID:23234360 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NCAN (Neurocan core protein). Expected localisation CNS processes (HPA tissue IHC); secreted protein (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A06700-1). Validated IHC antibody: A06700-1 at 1:100–1:500 (standard starting range) (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Synaptic glomeruli - capsule); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human glioma tissue; fixative not specified (datasheet A06700-1); 2. Fixation: Image fixative and duration unreported (datasheet A06700-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A06700-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06700-1); 8. Primary antibody: Rabbit anti-NCAN, 1:100–1:500 starting range (standard); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Secreted NCAN may stain away from RNA-positive cells (HPA tissue IHC); Isoform / epitope: 0 isoforms annotated; mature chain begins at residue 23 (UniProt); Regulation: Brain-enriched RNA (HPA tissue RNA). Evidence: UniProt O14594, HPA tissue IHC · Enhanced, HPA ICC-IF · Secreted, Datasheet A06700-1, PMC12571593, PMC10162530. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NCAN/immunohistochemistry-ihc-guide.